Literature DB >> 10417020

Correlates of herpes simplex virus seroprevalence among women attending a sexually transmitted disease clinic.

H Austin1, M Macaluso, A Nahmias, F K Lee, J Kelaghan, M Fleenor, E W Hook.   

Abstract

BACKGROUND: Infections by herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) are common in the United States. Herpes simplex virus type 2 is transmitted sexually, and the prevalence of antibodies to HSV-2 has increased in recent years. GOALS OF THIS STUDY: The objective of the present study was to estimate the seroprevalence of HSV-1 and HSV-2 antibodies among women attending a sexually transmitted disease (STD) clinic and to evaluate factors associated with HSV-1 and HSV-2 seropositivity. STUDY
DESIGN: The report describes a cross-sectional study conducted at an STD clinic. This study included 1,103 women between the ages of 18 and 35. Eighty-nine percent of the subjects were African Americans. The remaining subjects were white.
RESULTS: The overall prevalence of HSV-1 and HSV-2 antibodies among study subjects was 72% and 64%, respectively. Both HSV-1 and HSV-2 seropositivity were related directly to age and were higher among African Americans than whites. The prevalence of HSV-2 antibodies also increased with the number of lifetime sexual partners, an early age at first coitus, a history of syphilis, and the absence of HSV-1 antibodies. Drug use and recent use of barrier contraception were unrelated to either HSV-1 or HSV-2. COMMENT: Despite efforts by the public health community to prevent AIDS by promoting safe sexual practices, the prevalence of HSV-2 seropositivity has increased in recent years. Increased numbers of partners and an early age at first coitus are important correlates of HSV-2 infection. Public health interventions to prevent HSV-2 infection should target teenagers. Women of reproductive age attending STD clinics may also comprise an important target for interventions to prevent perinatal herpes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10417020     DOI: 10.1097/00007435-199907000-00004

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  7 in total

Review 1.  Recent advances: Sexually transmitted infections.

Authors:  R J Gilson; A Mindel
Journal:  BMJ       Date:  2001-05-12

2.  Case-crossover analysis of condom use and herpes simplex virus type 2 acquisition.

Authors:  Jeffrey D Stanaway; Anna Wald; Emily T Martin; Sami L Gottlieb; Amalia S Magaret
Journal:  Sex Transm Dis       Date:  2012-05       Impact factor: 2.830

3.  Genital herpes serotesting: a study of the epidemiology and patients' knowledge and attitude among STD clinic attenders in Coventry, UK.

Authors:  N Narouz; P S Allan; A H Wade; S Wagstaffe
Journal:  Sex Transm Infect       Date:  2003-02       Impact factor: 3.519

4.  Predictors of undiagnosed herpes simplex virus type 2 seropositivity among persons attending an HIV care clinic.

Authors:  Nicholas J Van Wagoner; Elizabeth Brown; Richard Whitley; Edward W Hook
Journal:  Sex Transm Dis       Date:  2012-11       Impact factor: 2.830

5.  A population based study of herpes simplex virus 2 seroprevalence in rural Costa Rica.

Authors:  A C Rodríguez; P E Castle; J S Smith; C Bratti; A Hildesheim; M Schiffman; R Viscidi; R D Burk; R L Ashley; X Castellsagué; R Herrero
Journal:  Sex Transm Infect       Date:  2003-12       Impact factor: 3.519

6.  Detection, quantification and genotyping of Herpes Simplex Virus in cervicovaginal secretions by real-time PCR: a cross sectional survey.

Authors:  Esther A N Aryee; Robin L Bailey; Angels Natividad-Sancho; Steve Kaye; Martin J Holland
Journal:  Virol J       Date:  2005-08-11       Impact factor: 4.099

7.  Herpes simplex virus type 2 seroprevalence in Korea: rapid increase of HSV-2 seroprevalence in the 30s in the southern part.

Authors:  Haeng Seop Shin; Jeong Joo Park; Chaeshin Chu; Hyeon Je Song; Kyung Soon Cho; Joo Shil Lee; Sung Soon Kim; Mee Kyung Kee
Journal:  J Korean Med Sci       Date:  2007-12       Impact factor: 2.153

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.